D.E. Shaw & Co’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$146M Buy
672,990
+1,354
+0.2% +$300K 0.09% 259
2025
Q4
$153M Sell
671,636
-447,509
-40% -$102M 0.08% 270
2025
Q3
$259M Sell
1,119,145
-421,708
-27% -$85.9M 0.15% 141
2025
Q2
$286M Buy
1,540,853
+918,609
+148% +$171M 0.2% 98
2025
Q1
$130M Buy
622,244
+397,071
+176% +$77.2M 0.12% 206
2024
Q4
$40M Sell
225,173
-401,734
-64% -$73.9M 0.03% 666
2024
Q3
$124M Sell
626,907
-291,724
-32% -$54.4M 0.11% 222
2024
Q2
$158M Buy
918,631
+178,932
+24% +$29.6M 0.15% 147
2024
Q1
$135M Sell
739,699
-326,055
-31% -$56.2M 0.12% 192
2023
Q4
$165M Sell
1,065,754
-54,054
-5% -$7.88M 0.14% 152
2023
Q3
$167M Sell
1,119,808
-543,840
-33% -$79.8M 0.17% 120
2023
Q2
$224M Buy
1,663,648
+1,532,290
+1,166% +$225M 0.23% 78
2023
Q1
$20.9M Buy
131,358
+5,112
+4% +$782K 0.02% 867
2022
Q4
$20.4M Buy
126,246
+11,663
+10% +$1.79M 0.02% 903
2022
Q3
$15.4M Buy
114,583
+12,772
+13% +$1.83M 0.02% 1029
2022
Q2
$15.6M Sell
101,811
-174,802
-63% -$26.7M 0.02% 1054
2022
Q1
$44.8M Buy
276,613
+2,481
+0.9% +$360K 0.04% 539
2021
Q4
$37.1M Buy
274,132
+33,958
+14% +$4.01M 0.03% 709
2021
Q3
$25.9M Buy
240,174
+167,678
+231% +$19.2M 0.02% 863
2021
Q2
$8.17M Buy
72,496
+52,250
+258% +$5.88M 0.01% 1668
2021
Q1
$2.19M Buy
20,246
+12,672
+167% +$1.36M ﹤0.01% 2509
2020
Q4
$812K Sell
7,574
-630,923
-99% -$60.6M ﹤0.01% 3160
2020
Q3
$55.9M Sell
638,497
-833,134
-57% -$78.4M 0.06% 380
2020
Q2
$144M Sell
1,471,631
-2,314,812
-61% -$204M 0.17% 109
2020
Q1
$288M Sell
3,786,443
-309,916
-8% -$26.4M 0.45% 29
2019
Q4
$363M Sell
4,096,359
-1,175,131
-22% -$97.6M 0.41% 24
2019
Q3
$399M Sell
5,271,490
-1,119,613
-18% -$76.8M 0.49% 21
2019
Q2
$465M Buy
6,391,103
+296,368
+5% +$23.3M 0.58% 16
2019
Q1
$491M Buy
6,094,735
+4,979,335
+446% +$407M 0.63% 10
2018
Q4
$103M Sell
1,115,400
-660,112
-37% -$58.1M 0.14% 164
2018
Q3
$168M Sell
1,775,512
-336,902
-16% -$31.9M 0.2% 100
2018
Q2
$196M Buy
2,112,414
+416,639
+25% +$40.7M 0.26% 74
2018
Q1
$161M Buy
1,695,775
+708,775
+72% +$77.9M 0.22% 95
2017
Q4
$95.5M Sell
987,000
-128,673
-12% -$12.1M 0.13% 183
2017
Q3
$99.1M Sell
1,115,673
-1,981,774
-64% -$151M 0.15% 158
2017
Q2
$225M Sell
3,097,447
-314,837
-9% -$21.2M 0.37% 39
2017
Q1
$222M Buy
3,412,284
+2,490,505
+270% +$157M 0.39% 37
2016
Q4
$57.7M Sell
921,779
-1,399,123
-60% -$85.4M 0.1% 243
2016
Q3
$146M Buy
2,320,902
+370,649
+19% +$24M 0.26% 70
2016
Q2
$121M Sell
1,950,253
-2,753,749
-59% -$168M 0.22% 96
2016
Q1
$269M Sell
4,704,002
-1,622,594
-26% -$90.4M 0.48% 28
2015
Q4
$375M Buy
6,326,596
+2,297,831
+57% +$132M 0.56% 21
2015
Q3
$219M Buy
4,028,765
+1,876,943
+87% +$122M 0.32% 53
2015
Q2
$145M Sell
2,151,822
-86,740
-4% -$5.66M 0.22% 88
2015
Q1
$131M Sell
2,238,562
-1,994,260
-47% -$120M 0.2% 102
2014
Q4
$277M Buy
4,232,822
+3,374,928
+393% +$213M 0.36% 40
2014
Q3
$49.6M Sell
857,894
-5,615,802
-87% -$312M 0.06% 350
2014
Q2
$365M Buy
6,473,696
+613,833
+10% +$32.2M 0.5% 26
2014
Q1
$301M Buy
5,859,863
+2,262,977
+63% +$114M 0.43% 30
2013
Q4
$190M Buy
3,596,886
+1,640,712
+84% +$80.6M 0.26% 61
2013
Q3
$87.5M Buy
1,956,174
+1,165,352
+147% +$51.7M 0.14% 155
2013
Q2
$32.7M Buy
+790,822
New +$34.6M 0.06% 346

Other funds holding ABBV

D.E. Shaw & Co's ABBV Position: Q1 2026 in Review

D.E. Shaw & Co increased its AbbVie (ABBV) stake by 0.2% in Q1 2026, buying an estimated $300K and bringing the position to 672,990 shares worth $146M. The position accounts for 0.09% of the portfolio, ranked #259.

D.E. Shaw & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $491M in Q1 2019. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • D.E. Shaw & Co held 672,990 shares of AbbVie worth $146M as of Q1 2026.
  • D.E. Shaw & Co bought 1,354 AbbVie shares in Q1 2026, an estimated $300K.
  • AbbVie made up 0.09% of D.E. Shaw & Co's portfolio in Q1 2026, its #259 holding.
  • D.E. Shaw & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's AbbVie position peaked at $491M in Q1 2019.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.